Sydney Eye Hospital has welcomed a cutting-edge addition to its ophthalmic oncology clinic: the ABSolu® Ultrasound Platform by Ellex. This state-of-the-art technology is now being used to monitor patients with complex eye conditions, such as rare ocular cancers, who require ongoing specialist care.
Ocular melanoma is a rare but serious disease, affecting around 7 million Australians each year. Despite its rarity, it is the most common primary eye cancer in adults, and up to 50% of patients with uveal melanoma will experience metastasis, often to the liver, even after successful treatment of the eye. Many patients remain asymptomatic until the disease has progressed, making early and accurate diagnosis absolutely vital.
The new ultrasound system offers unparalleled image quality and diagnostic precision, enabling clinicians to better assess and manage ocular tumours and other serious conditions.
Dr Li-Anne Lim, Ocular Oncologist, Cataract Surgeon, General Ophthalmologist says:
“We’re incredibly fortunate to have the new ABSolu Ultrasound Machine in our clinic. It allows us to use three different types of ultrasound in one unit to evaluate our oncology patients with greater accuracy and efficiency.”
How the ABSolu® Enhances Patient Care
A Scan Ultrasound: Measures the length of the eye, particularly useful in cases with dense cataracts. It also helps differentiate types such as choroidal melanomas, metastases, and haemangiomas.
B Scan Ultrasound: A high definition 20Hz probe provides detailed imaging of posterior segment tumours. It enables precise lesion measurements, which are critical for treatment planning and monitoring response.
Ultrasound Biomicroscopy (UBM): Offers high-resolution imaging of the anterior segment, including the cornea, iris, angle, and ciliary body. This is essential for assessing iris and ciliary body tumours—capabilities not commonly available in general ophthalmology clinics.
“We express our heartfelt thanks to the generous donors and the Sydney Eye Hospital Foundation for making this possible. Their support ensures we can continue delivering world-class care to patients.” Says Dr Li-Anne Lim
This investment in advanced diagnostic technology reflects the Foundation’s commitment to supporting excellence in eye care and improving outcomes for patients facing serious ocular diseases.
ABSolu® Enhances Patient Care
Pictured: Dr Li-Anne Lim, Dr Leah Kim, Patient.
